Role of EPO and TCF7L2 Gene Polymorphism Contribution to the Occurrence of Diabetic Retinopathy

Table 3

Frequences of genotypes and alleles of EPO and TCF7L genes polymorphisms in diabetes retinopathy patients and normal controls.

SNP	Genotype DR (%)	Normal controls (%)		value	OR (95% CI)
	Allele	()			()
	AA	(71.88%) 230	(56.60%) 133	≤0.001	1.960 (1.374-2.795)
	AC	(25.63%) 82	(40.00%) 94	≤0.001	0.517 (0.360-0.742)
rs551238; (EPO1)	CC	(2.50%) 8	(3.40%) 8	0.529	0.728 (0.269-1.967)
	A	(97.50%) 312	(96.60%) 227	0.001	1.690 (1.248-2.288)
	C	(28.13.3%) 90	(47.66%) 112	0.001	0.592 (0.437-0.801)
	GG	(1.88%) 6	(2.98%) 7	0.396	0.622 (0.206-1.877)
	GT	(26.89%) 86	(36.17%) 85	0.019	0.649 (0.451-0.933)
rs1617640; (EPO2)	TT	(71.25%) 228	(60.85%) 143	0.01	1.594 (1.116-2.278)
	G	(28.75.3%) 92	(39.15%) 92	0.013	0.678 (0.498-0.923)
	T	(98.13%) 314	(97.02%) 228	0.013	1.476 (1.084-2.010)
	CC	(87.19%) 279	(94.89%) 223	0.002	0.366 (0.188-0.713)
	CT	(12.81%) 41	(5.11%) 12	0.002	2.731 (1.402-5.320)
rs7903146; (TCF7L2)	TT	(0.00) 0	(0.00) 0
	C	(100.00%) 320	(100.00%) 235	0.003	0.383 (0.199-0.737)
	T	(12.81%) 41	(5.11%) 12	0.003	2.612 (1.357-5.028)

OR: odds ratio.